Abstract | PURPOSE: EXPERIMENTAL DESIGN: Twenty-five r/rMM subjects were treated in three cohorts with two doses of CART- BCMA cells ± cyclophosphamide. We retrospectively analyzed toxicity, response, and CART manufacturing data based on RT receipt. RESULTS: Thirteen subjects received no RT <1 year before CART infusion (Group A). Eight subjects received RT <1 year before CART infusion (Group B) with median time from RT to apheresis of 114 days (range 40-301). Four subjects received bridging-RT (Group C) with a median dose of 22 Gy and time from RT to infusion of 25 days (range 18-35). Group C had qualitatively lower rates of grade 4 (G4) hematologic toxicities (25%) versus A (61.5%) and B (62.5%). G3-4 neurotoxicity occurred in 7.7%, 25%, and 25% in Group A, B, and C, respectively. G3-4 cytokine release syndrome was observed in 38.5%, 25%, and 25% in Group A, B, and C, respectively. Partial response or better was observed in 54%, 38%, and 50% of Group A, B, and C, respectively. RT administered <1 year (P = 0.002) and <100 days (P = 0.069) before apheresis was associated with lower in vitro proliferation during manufacturing; however, in vivo CART- BCMA expansion appeared similar across groups. CONCLUSIONS: Bridging-RT appeared safe and feasible with CART- BCMA therapy in our r/rMM patients, though larger future studies are needed to draw definitive conclusions.
|
Authors | Shwetha H Manjunath, Adam D Cohen, Simon F Lacey, Megan M Davis, Alfred L Garfall, J Joseph Melenhorst, Russell Maxwell, W Tristram Arscott, Amit Maity, Joshua A Jones, John P Plastaras, Edward A Stadtmauer, Bruce L Levine, Carl H June, Michael C Milone, Ima Paydar |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 27
Issue 23
Pg. 6580-6590
(12 01 2021)
ISSN: 1557-3265 [Electronic] United States |
PMID | 34526365
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | ©2021 American Association for Cancer Research. |
Chemical References |
- B-Cell Maturation Antigen
- Receptors, Chimeric Antigen
|
Topics |
- B-Cell Maturation Antigen
- Humans
- Immunotherapy, Adoptive
(adverse effects)
- Multiple Myeloma
(drug therapy)
- Receptors, Chimeric Antigen
- Retrospective Studies
|